Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Nicholas, Adlard"'
Autor:
Helmut Butzkueven, Simon Broadley, Martin Merschhemke, Nicholas Riley, Michael Barnett, Anneke Van Der Walt, Pamela McCombe, Rob Walker, Nicholas Adlard, Naomi Burke, Imtiaz Samjoo
Publikováno v:
BMJ Neurology Open, Vol 6, Iss Suppl 1 (2024)
Externí odkaz:
https://doaj.org/article/ece597a258204edcbf206432cd426d8e
Autor:
Nicholas Riley, Christopher Drudge, Morag Nelson, Anja Haltner, Michael Barnett, Simon Broadley, Helmut Butzkueven, Pamela McCombe, Anneke Van der Walt, Erin O. Y. Wong, Martin Merschhemke, Nicholas Adlard, Rob Walker, Imtiaz A. Samjoo
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 17 (2024)
Background: Evidence from network meta-analyses (NMAs) and real-world propensity score (PS) analyses suggest monoclonal antibodies (mAbs) offer a therapeutic advantage over currently available oral therapies and, therefore, warrant consideration as a
Externí odkaz:
https://doaj.org/article/205e8fd314264a00a0dd54d3241d6b7a
Autor:
Virender Bhan, Fraser Clift, Moogeh Baharnoori, Kimberly Thomas, Barkha P Patel, Francois Blanchette, Nicholas Adlard, Umakanth Vudumula, Kapil Gudala, Nikkita Dutta, Daniel Grima, Soukaina Mouallif, Fatine Farhane
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 12, Iss 9 (2023)
Aim: The costs and consequences of initial and delayed ofatumumab treatment were evaluated in relapsing-remitting multiple sclerosis with active disease in Canada. Materials & methods: A Markov cohort model was used (10-year horizon, annual cycle l
Externí odkaz:
https://doaj.org/article/28912569120748138041870a3a8c4948
Autor:
Imtiaz A Samjoo, Christopher Drudge, Sarah Walsh, Santosh Tiwari, Roisin Brennan, Ibolya Boer, Dieter A Haring, Luisa Klotz, Nicholas Adlard, Judit Banhazi
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 12, Iss 7 (2023)
Aim: To assess the relative efficacy of disease-modifying therapies (DMTs) for relapsing multiple sclerosis (RMS) including newer therapies (ozanimod, ponesimod, ublituximab) using network meta-analysis (NMA). Materials & methods: Bayesian NMAs for
Externí odkaz:
https://doaj.org/article/edf22c04e4874c16822477f85d625256
Autor:
Vijayalakshmi Vasanthaprasad, Vivek Khurana, Sreelatha Vadapalle, Jackie Palace, Nicholas Adlard
Publikováno v:
BMC Neurology, Vol 22, Iss 1, Pp 1-20 (2022)
Abstract Background Secondary progressive multiple sclerosis (SPMS) is a subtype of multiple sclerosis (MS), which is a chronic neurological disease, characterised by inflammation of the central nervous system. Most of MS patients eventually progress
Externí odkaz:
https://doaj.org/article/e0991ea76d9d4de18ef082672dff4c04
Publikováno v:
Journal of Central Nervous System Disease, Vol 14 (2022)
Background In EXPAND (NCT01665144), a phase 3 randomized clinical trial, siponimod reduced disability progression versus placebo in patients with secondary progressive multiple sclerosis (SPMS). Aim To understand how a real-world population with SPMS
Externí odkaz:
https://doaj.org/article/3eb1ee58d0cb47cc93af9a72b803b5fe
Autor:
Moogeh, Baharnoori, Virender, Bhan, Fraser, Clift, Kimberly, Thomas, Soukaïna, Mouallif, Nicholas, Adlard, Philip, Cooney, François, Blanchette, Barkha P, Patel, Daniel, Grima
Publikováno v:
PharmacoEconomics - Open. 6:859-870
Ofatumumab is a high-efficacy disease-modifying therapy (DMT) approved for first-line treatment of relapsing-remitting multiple sclerosis (RRMS) in Canada.The aim of this study was to evaluate the cost effectiveness of ofatumumab from a Canadian heal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f44d876d250f6588064ef41c5c472f8
https://doi.org/10.1007/s41669-022-00363-1
https://doi.org/10.1007/s41669-022-00363-1
Autor:
Christopher Drudge, Melody Zhao, Satoru Tanaka, Nozomu Tanaka, Hiromichi Otaka, Izumi Kawachi, Dieter A. Häring, Róisín Brennan, Nicholas Adlard, Imtiaz A. Samjoo
Publikováno v:
Clinical and Experimental Neuroimmunology. 13:234-245
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e2c1c518b82660d85d2d7e0047f8299b
https://doi.org/10.1111/cen3.12717
https://doi.org/10.1111/cen3.12717
Autor:
Sophi Tatlock, Kate Sully, Anjali Batish, Chelsea Finbow, William Neill, Carol Lines, Roisin Brennan, Nicholas Adlard, Tamara Backhouse
Publikováno v:
The Patient - Patient-Centered Outcomes Research.
Aims: The aim of this study was to explore the experiences, values and preferences of people living with relapsing multiple sclerosis (PLwRMS) focusing on their treatments and what drives their treatment preferences. Methods: In-depth, semi-structure
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c25ec63d9f56704831a8c996cabc353
https://doi.org/10.1007/s40271-023-00617-y
https://doi.org/10.1007/s40271-023-00617-y
Publikováno v:
Journal of medical economics.
ObjectivesTo evaluate the impact of early (at first-line) vs delayed (3-year delay) ofatumumab initiation and long-term clinical, societal, and economic outcomes of ofatumumab vs teriflunomide in relapsing multiple sclerosis (RMS) patients from a Spa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bd8cfd423102613c7f6a4ff0408fff1
https://pubmed.ncbi.nlm.nih.gov/36472139
https://pubmed.ncbi.nlm.nih.gov/36472139